32nd General Annual Meeting of the Belgian Hematology Society

Final programme

(9) 10-11 February 2017
Dolce La Hulpe, Brussels

www.bhs.be
More Life
Better Life

SCIENTIFIC COMMITTEE - BHS BOARD MEMBERS AND FUNCTIONS
Fleur Samantha Benghiat
Dimitri Breems
Kristel Buvé
Barbara Cauwelier
Ann De Becker
Anne De Weweire
Chantal Doyen
Ann Janssens
Dominiek Mazure
Nathalie Meuleman
Cécile Springael
Nicole Straetmans
Ann Van de Velde
Marie-Christiane Vekemans
Evelyne Willems

Educational affairs
Councilor Scientific affairs
Councilor Clinical affairs
Treasurer
Secretary, Master of festivities
Councilor Committees
Patient affairs
Website
Transplant Registry
President
Councilor Committees
Clinical affairs
Nurse Committee
Vice president
Educational affairs

BHS & CONGRESS SECRETARIAT
Congress Care
P.O. Box 440
5201 AK ’s-Hertogenbosch
The Netherlands
Tel +31 (0)73 690 14 15
bhs@congresscare.com
www.congresscare.com
INTRODUCTION

Dear colleagues,

Welcome at the 32nd General Annual Meeting of the BHSI.

The board has arranged for a high-level scientific program which covers different hematology sub-specialties. The scientific presentations will cover new developments and current recommendations for treatment of hematological diseases, but also their diagnosis approach. Based on the success of the presentation « Cost of cancer treatments » last year, we decided to prolong this experience by creating an Ethics and Economy session that will bring up this year the topic of biosimilars. Another new session « Advances in laboratory technology » has been introduced with two presentations: the first one on minimal residual disease and the second one on next-generation sequencing. The research is once again brought to the forefront with among others the selected oral presentations, the commented poster walk and the awards for young researchers.

On Thursday February 9th, there are two events. The first one approaches an important mission of the BHS: the aid to patient organizations. After last year’s successful meeting, we are pleased to welcome anew the patient committees for interactive sessions. The second one is the reintroduction of the committees meeting. This will be a great opportunity to discover the committees activities but most importantly to benefit from their experience and promote interaction in the hematological community.

For several years the “Nurse symposium” has become a must of our meeting and it is with great enthusiasm that we will welcome them once again.

We encourage all colleagues to join us and discover this exciting program!

Nathalie Meuleman
President BHS
PROGRAM BHS COMMITTEE MEETING
THURSDAY 9 FEBRUARY 2017

15.00 - 16.15 Committee meeting part 1
- Welcome
  Chairs: Marie-Christiane Vekemans and Nathalie Meuleman
- Introduction
  Marie-Christiane Vekemans, Vice-president
- Lymphoproliferative disorders
  Ann Janssens
- Myeloma
  Chantal Doyen
- Myelodysplasia
  Stef Meers
- Myeloproliferative neoplasms
  Timothy Devos
- Red blood cell disorders
  Béatrice Gulbis

16.15 - 16.45 Break

16.45 - 18.00 Committee meeting part 2
- Marrow donor program
  Etienne Baudoux
- Transplantation
  Yves Beguin
- Nurses committee
  Martine Heylens
- Regulatory affairs
  Nathalie Meuleman
- JACIE
  Ivan Van Riet

18.00 Closing remarks
  Marie-Christiane Vekemans, Vice-president BHS
Canopée Auditorium
08.00 - 08.45 Registration

08.45 - 09.00 Welcome
Nathalie Meuleman, President BHS

09.00 - 10.00 Highlights on rare lymphoproliferative diseases
Chairs: Ann Janssens and Cécile Springael
How to diagnose and treat?
09.00 Lymphomas in the immunocompromised patients
Daan Dierickx, UZ Leuven
09.30 Primary central nervous system lymphoma
Andrés Ferreri, Milano, Italy

10.00 - 11.30 Advances in laboratory technology
Chairs: Dimitri Breems and Barbara Caeweller
10.00 Next generation sequencing in Hematology
Fabrice Jardin, Rouen, France
10.30 Minimal residual disease in acute myeloid leukemia
Peter Valk, Erasmus UMC, Rotterdam, the Netherlands

11.00 - 11.30 Coffee break

11.30 - 12.30 Satellite session 1 sponsored by Bristol-Meyers Squibb
Immuono- oncology: a new era in hematologic treatment
11:30 Making progress with I-O in hematology
Pierre Coulie, UCL – Ludwig Institute, Brussels
12:00 PD-1 pathway blockade in classical Hodgkin Lymphoma
Roch Houot, CHU de Rennes, France

12.30 - 13.30 Lunch and Commented Poster walk 1

13.30 - 15.00 Special lecture 1
Chairs: Kristel Buve and Evelyne Willems
Myelodysplastic syndromes and the new WHO classification
Gregor Verhoef, UZ Leuven

13.30 - 15.00 Selected ORAL ABSTRACTS
Chairs: Ann Van de Velde and Nicole Straetmans
13:30 A new frailty scoring in “clinically fit” older patients with malignant
hemopathies admitted to receive chemotherapy
Stephanie Dubruille, I.J. Bordet (ULB)
13:45 A single analysis for simultaneous measurement of all 4 DOACs
Jan Emmerechts, AZ Sint-Jan
14:00 Maternal Embryonic Leucine Zipper Kinase (MElk) drives a
high-risk gene network and represents an attractive novel drug
target in Multiple Myeloma and its associated bone disease
Arnold Bolomsky, Wilhelminenspital, Vienna, Austria
14:15 In vitro generation of tumor antigen-specific T cells from patient and
healthy donor stem cells
Sarahm Bonte, UZ Gent
14:30 Sequential administration of 5-azacytidine (AZA) and donor
lymphocyte infusion (DLI) for patients with acute myeloid leukemia
(AML) or myelodysplastic syndrome (MDS) in relapse after
allogeneic stem cell transplantation
Xavier Poiré, UCL Saint Luc
14:45 Successful transition from paediatric to adult care in Sickle Cell
Disease: An experience in a Belgian center.
Tracy Vandergraesen, Hopital Universitaire Des Enfants Reine Fabiola

15.00 - 15.30 Special lecture 1
Chairs: Kristel Buve and Evelyne Willems
Myelodysplastic syndromes and the new WHO classification
Gregor Verhoef, UZ Leuven

15.30 - 16.00 Coffee break

16.00 - 17.00 Pierre Stryckmans Lecture
Chair: Nathalie Meuleman and Marie-Christiane Vekemans
Acute promyelocytic leukemia: state of the art
Francesco Lo Coco, University Tor Vergata, Roma, Italy

17.00 - 18.00 Ethics and Economy
Chair: Nathalie Meuleman and Ann Janssens
Biosimilars in the Belgian health care plan
Maggie De Block, Federal Minister of Health, Belgium

18.00 - 19.00 Reception and commented Poster walk 2
PROGRAM GENERAL ANNUAL MEETING
SATURDAY 11 FEBRUARY 2017

Canopée Auditorium
08.30 - 09.00 GENERAL ASSEMBLY

09.00 - 10.00 Satellite session 2 sponsored by Janssen
09.00 Treatment of Multiple myeloma in the era of monoclonal antibodies
Niels van de Donk, VUMC Amsterdam, the Netherlands
09.30 Advances in the treatment of Chronic Lymphocytic Leukemia
Paolo Ghia, Milano, Italy

10.00 - 10.30 Special lectures 2
Chairs: Ann De Becker and Samantha Benghiat
10.00 Common variable immunodeficiency
Isabelle Meyts, UZ Leuven
10.30 Stopping tyrosine kinase inhibitors in Chronic Myeloid Leukemia
Delphine Rea, Paris, France Saint Louis Hospital

11.00 - 11.30 Coffee break

11.30 - 12.30 Satellite session 3 sponsored by Novartis
11.30 New insights in the treatment of Polycythemia Vera patients.
Claire Harrison, Guy’s and St Thomas’ Hospital, London, UK
12.00 JAK signaling in hematological malignancies, new horizons
Stefan Constantinescu, Ludwig Institute, Brussels

12.30 Awards for best oral and poster presentations
CLOSING
## PRELIMINARY PROGRAM NURSE MEETING
### FRIDAY 10 FEBRUARY 2017

### Baobab Auditorium

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.15</td>
<td>Welcome</td>
</tr>
<tr>
<td>09.30-11.00</td>
<td>Oral therapy in hematology anno 2017: a multidisciplinary approach</td>
</tr>
<tr>
<td>09.30</td>
<td>The view of the hematologist</td>
</tr>
<tr>
<td></td>
<td>Jan Van Droogenbroeck, AZ St-Jan Brugge</td>
</tr>
<tr>
<td>10.10</td>
<td>The eye of the pharmacist</td>
</tr>
<tr>
<td></td>
<td>Kim Herman, AZ St-Jan Brugge</td>
</tr>
<tr>
<td>10.35</td>
<td>The role of the specialist nurse</td>
</tr>
<tr>
<td></td>
<td>Ann Tegethoff, AZ St-Jan Brugge</td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>Coffee break</td>
</tr>
<tr>
<td>11.30-12.30</td>
<td>Motivational interviewing - How to engage, activate and empower your patients</td>
</tr>
<tr>
<td></td>
<td>Tim Anstiss, UK</td>
</tr>
<tr>
<td>12.30-12.30</td>
<td>Lunch and Commented Poster walk 1</td>
</tr>
<tr>
<td>13.30-14.30</td>
<td>ALL: Case studies</td>
</tr>
<tr>
<td></td>
<td>Carlos Graux, CHU UCL Namur</td>
</tr>
<tr>
<td>14.30-15.30</td>
<td>All people are different, but some people are more different than others</td>
</tr>
<tr>
<td></td>
<td>Patrice Van der Taelen, member of the Committee on Medical Ethics UZLeuven</td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Coffee break</td>
</tr>
</tbody>
</table>

### Canopée Auditorium

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00-16.30</td>
<td>Let’s Granny have a transplantation</td>
</tr>
<tr>
<td></td>
<td>Xavier Poire UCL</td>
</tr>
<tr>
<td></td>
<td>Saint Luc</td>
</tr>
<tr>
<td>16.00-17.00</td>
<td>PIERRE STRYCKMANS Lecture (no translation)</td>
</tr>
<tr>
<td>16.10</td>
<td>APL</td>
</tr>
<tr>
<td></td>
<td>Francesco Lo Coco, Roma, Italy</td>
</tr>
<tr>
<td>17.00-18.00</td>
<td>Biosimilars</td>
</tr>
<tr>
<td></td>
<td>Maggie De Block</td>
</tr>
</tbody>
</table>

### Baobab Auditorium

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00-16.30</td>
<td>Let’s Granny have a transplantation</td>
</tr>
<tr>
<td></td>
<td>Xavier Poire UCL</td>
</tr>
<tr>
<td></td>
<td>Saint Luc</td>
</tr>
</tbody>
</table>

### Canopée Auditorium

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00-17.00</td>
<td>PIERRE STRYCKMANS Lecture (no translation)</td>
</tr>
<tr>
<td>16.10</td>
<td>APL</td>
</tr>
<tr>
<td></td>
<td>Francesco Lo Coco, Roma, Italy</td>
</tr>
<tr>
<td>17.00-18.00</td>
<td>Biosimilars</td>
</tr>
<tr>
<td></td>
<td>Maggie De Block</td>
</tr>
</tbody>
</table>

### Reception and Commented Poster walk 2

18.00-19.00
At AbbVie, we build bonds with haematologists, oncologists, patients, payers, advocacy groups, health authorities, and other pharmaceutical companies, because we know that advancing the science of this devastating disease is not something that one person, or even one company, can do alone.

Together, we can conduct research that deepens our understanding of the disease and its pathways, to ultimately develop new molecules that make a transformational improvement in cancer care.

**BHS EVENTS APP**

**Download instructions**
The APP can be downloaded from the App Store and Google Play store. If you have not downloaded the BHS Events App yet, you will need to download that App first.

1. Download the BHS Events App
2. After completion: install BHS GAM 2017 into the BHS Events App
3. In case the App is already installed on your mobile device, please install the update
Committed to clinical development in oncology

BHS CORPORATE MEMBERS & BHS GAM SPONSORS

Platinum
- Bristol-Myers Squibb
- Janssen
- Novartis

Gold
- AbbVie
- Amgen
- Celgene
- Gilead
- Roche
- Takeda
- Teva

Silver
- MSD
- Mundipharma
- Pfizer Oncology

Bronze
- Binding Site
- Freenote
- Hevylite

Sponsors / exhibitors GAM 2017
- Alexion
- CSL Behring
- Incyte Biosciences
- Jazz Pharmaceuticals
- Leo Pharma
- Mallinckrodt Pharmaceuticals
- Sandoz
- Sanofi / Genzyme
- Shire
- SOBI
- Vifor Pharma
**CONTRAINDICATIONS**

- Hypersensitivity to this medicinal product
- Pregnancy
- Lactating women
- Children (safety and efficacy have not been established in children)

**PRECAUTIONS TO BE TAKEN IN SELECTION OF PATIENTS**

- Contraindication for patients with known hypersensitivity to lipegfilgrastim or to any of the excipients.

**PREGNANCY**

- Category L: there is no evidence of teratogenicity for this medicinal product. However, studies with recombinant human G-CSF in pregnant women have shown embryotoxic and fetotoxic effects. This medicinal product should not be used during pregnancy.

**LACTATION**

- This medicinal product is not compatible with breastfeeding. It is not recommended that breastfeeding be continued during treatment with this medicinal product.

**PEDIATRIC USE**

- The safety and efficacy of this medicinal product have not been established in children.

**EFFICACY AND SAFETY DATA**

- In 1025 paediatric patients treated with lipegfilgrastim, a bone marrow blast count ≥ 1,000/cmm has been observed in 14% of patients, 10% of which have been reported to be ≥ 50,000/cmm.

**SIDE EFFECTS**

- The most common side effects are related to the granulocyte-macrophage colony-stimulating factor (G-CSF) class and affect the hematologic system (e.g., bone pain, myalgia, flu-like symptoms).

**ADVERSE REACTIONS**

- **Table 1: Common and uncommon side effects of Lipegfilgrastim**

**REFERENCES**


**REGISTRATION FOR THE GENERAL ANNUAL MEETING 2017**

Registration via website www.BHS.be

- BHS Member (MD hematologists, MD specialists, Senior scientists) E 100
- BHS Junior member (MD trainees, PhD students) E 50
- Non-member E 200
- Nurses, lab. technicians, psychologists, data managers and quality managers: BHS Associate member - Nurse meeting only E 25
- BHS Associate member - GAM meeting (2 days) E 50
- Non Associate member - Nurse meeting only E 35
- Non Associate member - GAM meeting (2 days) E 70

**PLEASE NOTE**

- Only approved 2016 BHS members are entitled to register for the GAM at the discounted BHS membership registration fee. Payment of your 2016 membership fee should be settled before January 1st, 2017.

**ELECTIONS OF BOARD MEMBERS**

- Only regular members are allowed to vote. Information on e-voting will be send to members.

**ACCREDITATION**

- Accreditation for the General Annual Meeting is pending with specific accreditation for Ethics and Ecology + lecture on biosimilars

- Accreditation will only be registered if the online survey has been completed.

**EXHIBITION**

- A technical and pharmaceutical exhibition will be organized in conjunction with the annual meeting of the Belgian Hematology Society.
<table>
<thead>
<tr>
<th>Sprycel</th>
<th>Hospital Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 mg (30 tabs)</td>
<td>€ 3867.16</td>
</tr>
<tr>
<td>70 mg (60 tabs)</td>
<td>€ 4119.41</td>
</tr>
<tr>
<td>50 mg (60 tabs)</td>
<td>€ 4119.41</td>
</tr>
<tr>
<td>20 mg (60 tabs)</td>
<td>€ 2003.78</td>
</tr>
</tbody>
</table>

Approval date: 12/2015 - 729BE15PR14696-01